In this week’s Homerun Slides, the breakdown of the different CGM categories. To download the complete set in PowerPoint format, just use this link: New CGM Categories and Technologies Part 2. Catch up on past Homerun Slides for New CGM Categories and Technologies: New CGM Categories and Technologies Part 1.

Genetic predisposition is an important component of the multifactorial pathogenesis of T1DM. Although often diagnosed in individuals with no known family history of T1DM, the disease is about 15 times more common in siblings of a patient than in the general population. Siblings have an average risk of 6%, although individual risk varies significantly in relation to the extent of sharing predisposing genes with the proband, which allele variants are shared, and other factors. The risk to the offspring of affected mothers and fathers is about 2–3% and 6–7%, respectively. Among twins, the observed disease concordance rates are approximately 8–10% in dizygotic twins and, with extended follow-up, more than 60% in monozygotic twins.

In this Exclusive Interview transcript, Rachele Berria talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the results of studies such as the head-to-head trial of two long-acting basal insulins, and what Sanofi has in the pipeline.

In this Exclusive Interview, Rachele Berria talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the results of studies such as the head-to-head trial of two long-acting basal insulins.

In part 1 of this Exclusive Interview, Rachele Berria talks with Diabetes in Control Publisher Steve Freed about the various trials of interest presented at the conference, such as the latest regarding the study of two basal insulins.

In part 2 of this Exclusive Interview, Rachele Berria talks with Diabetes in Control Publisher Steve Freed about the products in the works at Sanofi.

In part 3, the conclusion of this Exclusive Interview, Rachele Berria talks with Diabetes in Control Publisher Steve Freed about the focus on the impact of certain medications on specific populations.

Health expenditure greater for person with two diseases simultaneously than for the diseases separately

My wife is heading in to her first appointment with an endocrinologist. After 3 years of controlling her glucose with long acting insulin, a GLP-1 analog and an SGLT-2I, she had to go on meal time insulin. The use of meal time insulin forced her to check her glucose more …

New technologies have the potential to revolutionize diabetes care. But what are the advantages and disadvantages of insulin pumps, vs. daily injections? How widely will they be adopted, by patients with type 2 diabetes as well as type 1? What factors will make a difference for adoption – convenience, accuracy, costs? In November, we asked you to help us examine the future of insulin delivery and find the answers to these questions. Now we’re sharing all the results with you, so that you can see for yourself how your fellow members of the diabetes community plan on using CGMs, now and in the future.